IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10399945 B1

PDFFull Text
Date of Patent:
Sep. 03, 2019

Filed:

Sep. 21, 2018

Tetrahydronaphthyl urea derivative

Applicant:

Mochida Pharmaceutical Co., Ltd., Tokyo, JP;

Inventors:

Fumihiko Saitoh, Tokyo, JP;

Hiroshi Nagasue, Tokyo, JP;

Assignee:

MOCHIDA PHARMACEUTICAL CO., LTD., Tokyo, JP;

Attorney:

Birch, Stewart, Kolasch & Birch, LLP

Primary Examiner:

Emily A Bernhardt

Int. Cl.
CPC ...
C07D 213/89 (2006.01); C07D 401/04 (2006.01); C07D 405/04 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01); A61P 17/06 (2006.01); A61P 25/00 (2006.01); A61P 35/00 (2006.01); C07D 213/75 (2006.01); A61K 31/4418 (2006.01); A61K 31/506 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); C07D 213/84 (2006.01); A61K 31/4433 (2006.01); C07D 405/14 (2006.01); C07D 213/81 (2006.01); C07D 413/12 (2006.01); A61K 45/06 (2006.01); A61K 45/00 (2006.01); C07C 213/10 (2006.01); C07C 215/44 (2006.01); A61P 1/16 (2006.01); A61P 1/02 (2006.01); A61P 31/00 (2006.01); A61P 3/06 (2006.01); A61P 3/04 (2006.01); A61P 1/00 (2006.01); A61P 21/02 (2006.01); A61P 13/02 (2006.01); A61P 11/00 (2006.01); A61P 37/06 (2006.01); A61P 25/24 (2006.01); A61P 15/00 (2006.01); A61P 29/02 (2006.01); A61P 13/10 (2006.01); A61P 25/04 (2006.01); A61P 25/16 (2006.01); A61P 25/20 (2006.01); A61P 21/00 (2006.01); A61P 9/06 (2006.01); A61P 9/00 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); A61P 5/14 (2006.01); A61P 35/02 (2006.01); A61P 19/10 (2006.01); A61P 1/18 (2006.01); A61P 37/00 (2006.01); A61P 13/08 (2006.01); A61P 31/18 (2006.01); A61P 11/04 (2006.01); A61P 17/00 (2006.01); A61P 13/12 (2006.01); A61P 11/06 (2006.01); A61P 11/02 (2006.01); A61P 1/04 (2006.01); A61P 19/02 (2006.01); A61P 43/00 (2006.01); A61P 7/00 (2006.01); A61P 9/12 (2006.01); A61P 25/08 (2006.01); A61P 3/10 (2006.01);
U.S. Cl.
CPC ...
C07D 213/75 (2013.01); A61K 31/444 (2013.01); A61K 31/4418 (2013.01); A61K 31/4433 (2013.01); A61K 31/4439 (2013.01); A61K 31/506 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 1/02 (2018.01); A61P 1/04 (2018.01); A61P 1/16 (2018.01); A61P 1/18 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 5/14 (2018.01); A61P 7/00 (2018.01); A61P 9/00 (2018.01); A61P 9/06 (2018.01); A61P 9/12 (2018.01); A61P 11/00 (2018.01); A61P 11/02 (2018.01); A61P 11/04 (2018.01); A61P 11/06 (2018.01); A61P 13/02 (2018.01); A61P 13/08 (2018.01); A61P 13/10 (2018.01); A61P 13/12 (2018.01); A61P 15/00 (2018.01); A61P 17/00 (2018.01); A61P 19/02 (2018.01); A61P 19/10 (2018.01); A61P 21/00 (2018.01); A61P 21/02 (2018.01); A61P 25/00 (2018.01); A61P 25/04 (2018.01); A61P 25/08 (2018.01); A61P 25/16 (2018.01); A61P 25/20 (2018.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); A61P 29/02 (2018.01); A61P 31/00 (2018.01); A61P 31/18 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 37/00 (2018.01); A61P 37/06 (2018.01); A61P 43/00 (2018.01); C07C 213/10 (2013.01); C07C 215/44 (2013.01); C07D 213/81 (2013.01); C07D 213/84 (2013.01); C07D 401/04 (2013.01); C07D 405/04 (2013.01); C07D 405/14 (2013.01); C07D 413/12 (2013.01); C07D 417/04 (2013.01); C07B 2200/07 (2013.01);
Abstract

The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like). Specifically, the present invention provides a compound or an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or the like, the compound represented by formula (I):

Find Patent Forward Citations

Loading…